

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

**CHANGES IN DIRECTORS
AND
PROPOSED AMENDMENTS TO THE ARTICLES OF
ASSOCIATION AND THE RULES OF PROCEDURE
FOR THE GENERAL MEETING OF SHAREHOLDERS**

Changes in Directors

The board of directors (the “**Board**”) of Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”) hereby announces the following changes of members of the Board:

Resignation of Directors

Mr. Sun Hongbin (“**Mr. Sun**”) has tendered his resignation from his positions as a non-executive director, the chairperson of the Board, the chairperson of the strategy and development committee, a member of the remuneration and appraisal committee and a member of commercialisation committee of the Company with effect from the conclusion of the upcoming extraordinary general meeting of the Company (the “**EGM**”) due to the need to devote more time to other business commitment.

Ms. Fang Cong (“**Ms. Fang**”) has tendered her resignation from her positions as an executive director of the Company and a member of the nomination committee of the Company with effect from the conclusion of the upcoming EGM due to the need to devote more time to other business commitment.

Dr. Li Minghua (“**Dr. Li**”) has tendered his resignation from his position as an independent non-executive director of the Company, the chairperson of the remuneration and appraisal committee, and a member of the audit committee, the nomination committee and the strategy and development committee of the Company with effect from the conclusion of the upcoming EGM due to the need to devote more time to other business commitment.

Mr. Sun, Ms. Fang and Dr. Li have confirmed that they have no disagreement with the Board, and there is no matter relating to their resignations that needs to be brought to the attention of the shareholders of the Company. The Board would like to express sincere gratitude to Mr. Sun, Ms. Fang and Dr. Li for their valuable contribution to the Company during their tenures of office.

Proposed Appointment of Non-executive Director

The Board resolved to nominate Dr. Chang Zhaohua (“**Dr. Chang**”), Mr. Hiroshi Shirafuji (“**Mr. Shirafuji**”), Mr. Norihiro Ashida (“**Mr. Ashida**”) and Ms. Liang Min (“**Ms. Liang**”) as non-executive directors of the Company. The proposed appointments of Dr. Chang, Mr. Shirafuji, Mr. Ashida and Ms. Liang as non-executive directors of the Company are subject to the consideration and approval by the shareholders of the Company at the EGM.

The biographical details of Dr. Chang, Mr. Shirafuji, Mr. Ashida and Ms. Liang are as follows:

Dr. Chang Zhaohua (常兆華)

Dr. Chang Zhaohua, aged 62. Dr. Chang has over 34 years’ experience in the medical device industry, and currently serves as the chairman, executive director and chief executive officer of MicroPort Scientific Corporation (“**MPSC**”) (a controlling shareholder of the Company and a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), stock code: 00853), the chairman of the board and the non-executive director of MicroPort NeuroScientific Corporation (a company listed on the Stock Exchange, stock code: 02172) and a professor at School of Medical Device, University of Shanghai for Science and Technology. Before establishing Shanghai MicroPort Medical (Group) Co., Ltd. (上海微創醫療器械(集團)有限公司) in 1998, from 1996 to 1997, Dr. Chang served as vice president of R&D at Endocare Inc., a NASDAQ listed medical device company based in California, U.S.. From 1990 to 1995, Dr. Chang served as senior engineer, chief scientist, director of R&D and vice president of Engineering at Cryomedical Sciences Inc., a public medical device company in Maryland U.S..

Dr. Chang received his bachelor’s degree in refrigeration engineering in 1983 and master’s degree in cryogenic engineering in 1985, both from University of Shanghai for Science and Technology and received his doctoral degree in biological science from State University of New York (Binghamton) in 1992. Dr. Chang has published extensively in biomedical fields and holds several dozens of patents in the United States and in China.

Dr. Chang is interested in 49,047,671 underlying shares of MPSC by virtue of the share options granted to him under the share scheme(s) of MPSC. Dr. Chang is also interested in

6,000,000 underlying shares by virtue of the share options granted to him under the share scheme of MicroPort CardioFlow Medtech Corporation.

Save as disclosed above, (i) Dr. Chang does not hold any other positions with the Company and/or its subsidiaries; (ii) Dr. Chang does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) Dr. Chang does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Dr. Chang does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”).

As at the date of this announcement, there are no other matters relating to the proposed appointment of Dr. Chang that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and there are no other matters relating to the proposed appointment of Dr. Chang that need to be brought to the attention of the shareholders of the Company.

Mr. Hiroshi Shirafuji (白藤泰司)

Mr. Hiroshi Shirafuji, aged 81. Mr. Shirafuji served as a non-executive director of MPSC from November 2006 to June 2020 and from June 2023 to September 2025, and currently serves as the advisor of MPSC. Mr. Shirafuji was an executive director of Otsuka Medical Devices Co., Ltd. (“OMD”) from January 2017 to March 2017. From February 2011 to January 2017, he served as the president and representative director of OMD. Prior to joining OMD in February 2011, he was an executive director responsible for pharmaceuticals marketing at Otsuka Pharmaceutical Co., Ltd. (“Otsuka Pharmaceutical”) from 1997 to 1998. Mr. Shirafuji joined Otsuka Pharmaceutical in 1967.

Mr. Shirafuji received his bachelor’s degree in economics from Doshisha University in Kyoto in 1967.

Save as disclosed above, (i) Mr. Shirafuji does not hold any other positions with the Company and/or its subsidiaries; (ii) Mr. Shirafuji does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) Mr. Shirafuji does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Mr. Shirafuji does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

As at the date of this announcement, there are no other matters relating to the proposed appointment of Mr. Shirafuji that are required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules and there are no other matters relating to the proposed

appointment of Mr. Shirafuji that need to be brought to the attention of the shareholders of the Company.

Mr. Norihiro Ashida (蘆田典裕)

Mr. Norihiro Ashida, aged 70. Mr. Ashida served as a non-executive director of MPSC from November 2006 to September 2025, and currently serves as the advisor of MPSC. Mr. Ashida was appointed as audit and supervisory board member of Cuorips Inc. (a company listed on the Tokyo Stock Exchange, stock code: 4894) with effect from 1 July 2024. Mr. Ashida has served as a director of J-Pharma Co., Ltd. since June 2021. From February 2011 to June 2022, Mr. Ashida successively served as a director and advisor of Otsuka Medical Devices, a subsidiary of Otsuka Holdings Co., Ltd. (“**Otsuka Holdings**”). Mr. Ashida was an executive operating officer of Otsuka Holdings and the director of its business development and planning department until 2015. Before joining Otsuka Pharmaceutical in April 2003, he was a general manager of Mizuho Corporate Bank Ltd. from 2002 to 2003. From 1999 to 2002, Mr. Ashida was a general manager of the Industrial Bank of Japan (“**IBJ**”), where he headed the credit department for western Japan. From 1995 to 1999, Mr. Ashida served as vice president responsible for business development at 3iBJ Ltd., a venture capital firm formed by 3i Group plc and IBJ. From 1989 to 1995, Mr. Ashida was a senior vice president of IBJ (Canada). He joined IBJ in 1977 in its Tokyo branch.

Mr. Ashida received his bachelor’s degree in economics from the University of Tokyo in 1977.

Save as disclosed above, (i) Mr. Ashida does not hold any other positions with the Company and/or its subsidiaries; (ii) Mr. Ashida does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) Mr. Ashida does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Mr. Ashida does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

As at the date of this announcement, there are no other matters relating to the proposed appointment of Mr. Ashida that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the proposed appointment of Mr. Ashida that need to be brought to the attention of the shareholders of the Company.

Ms. Liang Min (梁敏)

Ms. Liang Min, aged 39. Ms. Liang joined MicroPort Sinica Co., Ltd. in April 2021 and is currently the business director of its overseas business department. Since November 2023, Ms. Liang serves as the chairwoman of the board of supervisors of Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (上海微創心脈醫療科技(集團)股份有限公司) (a company listed on the Shanghai Stock Exchange, stock code: 688016). Prior to that, Ms. Liang was a marketing manager of Abbott Laboratories Trading (Shanghai) Co., Ltd. (雅培醫療器械貿易(上海)有限公司) from April 2011 to April 2021, and a senior sales representative of Johnson & Johnson Medical (China) Ltd. (強生(中國)醫療器材有限公司) from July 2008 to March 2011.

Ms. Liang holds a bachelor's degree from Department of Chemistry, Fudan University and a master's degree in global executive master of business administration (Global EMBA) from China Europe International Business School.

Save as disclosed above, (i) Ms. Liang does not hold any other positions with the Company and/or its subsidiaries; (ii) Ms. Liang does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) Ms. Liang does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Ms. Liang does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

As at the date of this announcement, there are no other matters relating to the proposed appointment of Ms. Liang that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the proposed appointment of Ms. Liang that need to be brought to the attention of the shareholders of the Company.

Upon the proposed appointments of Dr. Chang, Mr. Shirafuji, Mr. Ashida and Ms. Liang being approved by the shareholders of the Company, they will enter into letters of appointment with the Company for a term not more than three years commencing from the date of being elected at the EGM until the expiry of the term of the second session of the Board. Mr. Shirafuji and Mr. Ashida will be entitled to receive director's fees of RMB120,000 (or equivalent foreign currency) per annum, respectively, which was determined by the remuneration and appraisal committee of the Company with reference to their positions and responsibilities within the Company and market benchmarks. Dr. Chang and Ms. Liang will not receive any director's fees from the Company during their tenures.

Proposed Appointment of Independent Non-executive Director

The Board resolved to nominate Mr. Jonathan H. Chou (“**Mr. Chou**”) and Dr. Guoen Liu (“**Dr. Liu**”) as independent non-executive directors of the Company. The proposed appointments of Mr. Chou and Dr. Liu as independent non-executive directors of the Company are subject to the consideration and approval by the shareholders of the Company at the EGM.

The biographical details of Mr. Chou and Dr. Liu are as follows:

Mr. Jonathan H. Chou (周嘉鴻)

Mr. Jonathan H. Chou, aged 61. Mr. Chou was appointed as an independent non-executive director of MPSC on 3 September 2010. He is a seasoned finance executive and advisor with over 30 years of international experience across the semiconductor, electronics and industrial sectors. Mr. Chou was most recently the chief financial officer of UTAC Holdings Ltd., a global semiconductor assembly and test services provider, where he also oversaw the group’s information technology and human resources functions.

Prior to that, he served as chief financial officer of Kulicke & Soffa Industries, Inc. (Nasdaq: KLIC), a leading provider of semiconductor packaging and electronic assembly solutions, and concurrently held the position of interim chief executive officer from 2015 to 2016. During his tenure, he was also responsible for the company’s global IT and facilities operations. Earlier in his career, he held senior finance leadership roles with multinational corporations including Honeywell, Tyco ADT, Lucent Technologies Bell Labs, and Public Service Enterprise Group.

Mr. Chou currently serves as an independent non-executive director of MicroPort CardioFlow Medtech Corporation (a company listed on the Stock Exchange, stock code: 02160). He is also chairman of the board of the Emerging Markets Investors Alliance, a not-for-profit organization promoting sustainable governance among institutional investors, and advises several private-equity-backed companies including AddVita Pte. Ltd., an Asian healthcare distribution platform backed by SeaTown (a Temasek-linked fund).

Mr. Chou holds a MBA from Duke University’s Fuqua School of Business and a B.A. in Economics from the University at Buffalo. He has served since 2013 on the East Asia Regional Advisory Board of Duke University’s Fuqua School of Business.

Mr. Jonathan H. Chou is interested in (i) 161,290 underlying shares of MPSC by virtue of the share options granted to him under the share scheme(s) of MPSC and (ii) 6,300 shares of MPSC. Mr. Chou is also interested in 449,683 underlying shares by virtue of the share options granted to him under the share scheme of MicroPort CardioFlow Medtech Corporation.

Save as disclosed above, (i) Mr. Chou does not hold any other positions with the Company and/or its subsidiaries; (ii) Mr. Chou does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) Mr. Chou does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Mr. Chou does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

As at the date of this announcement, there are no other matters relating to the proposed appointment of Mr. Chou that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the proposed appointment of Mr. Chou that need to be brought to the attention of the shareholders of the Company.

Dr. Guoen Liu (劉國恩)

Dr. Guoen Liu, aged 68. Dr. Liu was appointed as an independent non-executive director of MPSC on 3 September 2010. Dr. Liu is a noted scholar in the fields of health and development economics, health reform and pharmaceutical economics. Dr. Liu currently serves as Dean of Peking University Institute for Global Health and Development, MOE Yangtze River Scholar distinguished professor of economics at the Peking University National School of Development. From 2000 to 2006, Dr. Liu served as a tenured associate professor of University of North Carolina at Chapel Hill. From 1994 to 2000, Dr. Liu was assistant professor of University of Southern California. Dr. Liu also serves as editor or associate editor in various domestic and international academic journals in the field of health economics and pharmaceutical economics. From February 2021 to July 2024, Dr. Liu was an independent director of SciClone Pharmaceuticals (Holdings) Limited (賽生藥業控股有限公司, a company listed on the Stock Exchange, stock code: 06600, and the listing of its shares was withdrawn with effect from 5 July 2024). Dr. Liu is currently an independent director of Yunnan Baiyao Group Co., Ltd. (雲南白藥集團股份有限公司, a company listed on Shenzhen Stock Exchange (stock code: 000538)).

Dr. Liu received his bachelor's degree in mathematics from Southwest Minzu University in 1981, his master's degree in statistics from Southwestern University of Finance and Economics in 1985, his Ph.D. in economics from the City University of New York Graduate Center in 1991, and completed postdoctoral studies in health economics from Harvard University in 1994.

Dr. Guoen Liu is interested in 161,290 underlying shares of MPSC by virtue of the share options granted to him under the share scheme(s) of MPSC.

Save as disclosed above, (i) Dr. Liu does not hold any other positions with the Company and/or its subsidiaries; (ii) Dr. Liu does not, nor did he in the past three years, hold any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (iii) Dr. Liu does not have any relationships with any directors, supervisors, senior management, substantial shareholders or controlling shareholders of the Company; and (iv) Dr. Liu does not have any interest in the shares of the Company within the meaning of Part XV of the SFO.

As at the date of this announcement, there are no other matters relating to the proposed appointment of Dr. Liu that are required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters relating to the proposed appointment of Dr. Liu that need to be brought to the attention of the shareholders of the Company.

Upon the proposed appointments of Mr. Chou and Dr. Liu being approved by the shareholders of the Company, they will enter into letters of appointment with the Company for a term not more than three years commencing from the date of being elected at the EGM until the expiry of the term of the second session of the Board. Mr. Chou and Dr. Liu will be entitled to receive director's fees of RMB120,000 (or equivalent foreign currency) per annum, respectively, which was determined by the remuneration and appraisal committee of the Company with reference to their positions and responsibilities within the Company and market benchmarks.

Reasons for Proposed Appointment of Directors

The Company has established the nomination committee to review and optimize the composition of the Board and to make recommendations to the Board regarding the appointment plans for directors. The Company has also adopted a board diversity policy, recognizing and embracing the benefits of having a diverse Board, and sees increasing diversity at the Board level as an essential element in supporting the attainment of the Company's strategic objectives and sustainable development.

The Board believes that Dr. Chang, Mr. Shirafuji, Mr. Ashida, Ms. Liang, Mr. Chou and Dr. Liu possess the character, qualifications and integrity required to serve as directors of the Company. Their professional qualifications, skills, knowledge and experience relevant to the Company's business and corporate strategy will further enhance the diversity of the Board, which will help the Board to consider issues from different perspectives, so as to make decisions in the best interests of the Company and its shareholders after appropriate review and assessment.

The Board believes that the joining of the aforementioned six directors will further enrich the Board's mix of knowledge, skills and experience, including but not limited to the academic fields of medical device industry, biomedicine industry, finance and banking, international market commercial management, health and development economics. They will also provide the Company with rich experience in different economic markets. With the joining of Mr. Chou and Dr. Liu, the Company will have four independent non-executive directors, each with diverse industry backgrounds, including accounting and finance, financial and banking, law and economics.

The nomination committee will continue to review the composition of the Board from time to time, and discuss the Board structure to ensure that it has a balance of expertise, skills and experience appropriate for the requirements of the business of the Company.

Proposed Amendments to the Articles of Association and the Rules of Procedure for the General Meeting of Shareholders

In view of the above changes in directors, the Board proposed that the number of Board seats specified in the articles of association of the Company (the "**Articles of Association**") be increased from 8 to 11, and making other consequential, tidy-up and housekeeping amendments (the "**Proposed Amendments to the Articles of Association**") to optimise the composition of the Board.

In view of the Proposed Amendments to the Articles of Association, the Board proposed to amend the Rules of Procedure for the General Meeting of Shareholders accordingly.

The Proposed Amendments to the Articles of Association and the Rules of Procedure for the General Meeting of Shareholders shall be considered and approved by the shareholders of the Company by way of special resolutions at the EGM, and will become effective upon approval by the shareholders of the Company at the EGM.

General Information

The appointment of the above directors shall also be subject to the approval of the Proposed Amendments to the Articles of Association and the Rules of Procedure for the General Meeting of Shareholders at the EGM.

A circular, containing, among other things, details of the above resolutions will be despatched to the shareholders of the Company in due course.

By Order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 5 November 2025

As at the date of this announcement, the executive directors are Dr. He Chao, Mr. Liu Yu and Ms. Fang Cong, the non-executive directors are Mr. Sun Hongbin and Mr. Chen Chen, and the independent non-executive directors are Dr. Li Minghua, Mr. Yao Haisong and Mr. Chung Wai Man.